EntryIndia LogoEntryIndia

Covid treatment: Zydus gets SEC nod for clinical trials of antibodies cocktail

Updated Jun 05, 2021 03:57 am

  • Domestic pharma major Zydus Cadila has received the permission of the Subject Expert Committee (SEC) to conduct clinical trials of its monoclonal antibodies (mAbs)-based cocktail for the treatment of Covid-19, reported ANI.
  • "SEC gives a recommendation for the phase 1 and 2 clinical trials of Zydus Cadila's biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild Covid-19," the news agency quoted a source as saying.
Read More..

Tags: covid treatment Zydus SEC anitibodies